ICML 2023

Data Support Liso-Cel for Relapsed or Refractory CLL/SLL

By

Jen Smith

Publish Date June 27, 2023

New research suggests that lisocabtagene maraleucel (liso-cel) is a potential treatment option for relapsed or refractory CLL/SLL.

Intensified ABVD Bests PET-Adapted ABVD as First-Line Therapy for Hodgkin Lymphoma

By

Andrea S. Blevins Primeau, PhD, MBA

Publish Date June 26, 2023

Intensified ABVD can improve outcomes, when compared with PET-adapted ABVD, in patients with previously untreated Hodgkin lymphoma, a phase 3 study suggests.

HDC-ASCT Improves Survival vs Immunochemotherapy in Primary CNS Lymphoma

By

Leah Lawrence

Publish Date June 22, 2023

HDC-ASCT improves outcomes vs immunochemotherapy in newly diagnosed primary CNS lymphoma, a phase 3 study suggests.

Acalabrutinib Plus Rituximab “Highly Effective” in Older MCL Patients

By

Erin Clancy

Publish Date June 21, 2023

Acalabrutinib and rituximab can yield early complete responses in older patients with previously untreated mantle cell lymphoma.

Risk-Adapted Treatment Approach Produces Durable Remissions in MCL

By

Julie Ehlers

Publish Date June 20, 2023

A risk-adapted treatment approach can produce durable responses in younger patients with mantle cell lymphoma, a phase 2 trial suggests.